Edwards Lifesciences Corporation

DB:EWL Stock Report

Market Cap: €42.3b

Edwards Lifesciences Valuation

Is EWL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EWL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EWL (€70.44) is trading above our estimate of fair value (€64.16)

Significantly Below Fair Value: EWL is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EWL?

Key metric: As EWL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EWL. This is calculated by dividing EWL's market cap by their current earnings.
What is EWL's PE Ratio?
PE Ratio27.8x
EarningsUS$1.57b
Market CapUS$43.59b

Price to Earnings Ratio vs Peers

How does EWL's PE Ratio compare to its peers?

The above table shows the PE ratio for EWL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.1x
SHL Siemens Healthineers
29.5x14.2%€57.3b
AFX Carl Zeiss Meditec
22.5x16.1%€4.0b
EUZ Eckert & Ziegler
25.1x5.2%€900.9m
DRW3 Drägerwerk KGaA
7.4x2.0%€785.0m
EWL Edwards Lifesciences
27.8x4.8%€43.6b

Price-To-Earnings vs Peers: EWL is expensive based on its Price-To-Earnings Ratio (27.8x) compared to the peer average (21.1x).

Price to Earnings Ratio vs Industry

How does EWL's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
EWL 27.8xIndustry Avg. 30.7xNo. of Companies8PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: EWL is good value based on its Price-To-Earnings Ratio (27.8x) compared to the European Medical Equipment industry average (30.7x).

Price to Earnings Ratio vs Fair Ratio

What is EWL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EWL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.8x
Fair PE Ratio28.6x

Price-To-Earnings vs Fair Ratio: EWL is good value based on its Price-To-Earnings Ratio (27.8x) compared to the estimated Fair Price-To-Earnings Ratio (28.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EWL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€70.44
€77.47
+10.0%
9.3%€94.32€66.26n/a29
Dec ’25€67.88
€72.51
+6.8%
9.8%€91.62€59.63n/a28
Nov ’25€62.12
€70.59
+13.6%
9.8%€89.49€58.24n/a28
Oct ’25€59.04
€70.16
+18.8%
9.6%€87.45€58.72n/a27
Sep ’25€63.07
€75.22
+19.3%
11.1%€93.67€60.03n/a27
Aug ’25€57.55
€75.22
+30.7%
11.1%€93.67€60.03n/a27
Jul ’25€84.57
€89.50
+5.8%
10.2%€99.70€65.23n/a27
Jun ’25€80.81
€89.15
+10.3%
9.6%€98.80€67.41n/a28
May ’25€79.65
€88.96
+11.7%
9.5%€97.93€68.09n/a28
Apr ’25€88.92
€85.85
-3.5%
9.2%€97.34€66.74n/a28
Mar ’25€78.60
€84.46
+7.5%
8.3%€97.15€66.61n/a28
Feb ’25€74.00
€73.64
-0.5%
12.3%€88.32€52.44n/a28
Jan ’25€69.00
€72.36
+4.9%
12.3%€87.25€51.81€72.0228
Dec ’24€62.44
€73.02
+16.9%
14.4%€92.85€51.89€67.8828
Nov ’24€59.44
€77.07
+29.7%
13.8%€96.52€59.62€62.1227
Oct ’24€65.90
€90.48
+37.3%
8.8%€104.05€70.94€59.0426
Sep ’24€70.30
€87.49
+24.4%
8.8%€100.16€68.29€63.0724
Aug ’24€74.78
€87.49
+17.0%
8.8%€100.16€68.29€57.5524
Jul ’24€86.28
€87.06
+0.9%
8.5%€97.59€67.85€84.5723
Jun ’24€78.52
€87.06
+10.9%
8.5%€97.59€67.85€80.8123
May ’24€79.00
€84.15
+6.5%
8.7%€95.29€66.25€79.6522
Apr ’24€76.09
€80.09
+5.3%
9.6%€92.25€61.81€88.9222
Mar ’24€74.00
€83.62
+13.0%
13.5%€121.10€62.41€78.6022
Feb ’24€71.25
€80.64
+13.2%
14.1%€118.34€60.08€74.0022
Jan ’24€70.10
€85.99
+22.7%
16.0%€122.43€64.04€69.0023

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 05:04
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Edwards Lifesciences Corporation is covered by 73 analysts. 33 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James Francis MainwaringAtlantic Equities LLP
David RescottBaird
Ishan MajumdarBaptista Research